EW — Edwards Lifesciences Corporation

Constructive analyst consensus (33 Buy, 16 Hold, 0 Sell; consensus target $102.44) and double-digit Q2 revenue growth outweigh a minor FDA recall headline; as of 2026-10-20 the stock sat mid-range with RSI 54.2 and a $74.66-$96.29 52-week range.

Revenue growth has been strong and broadly stable: Q2 2026 revenue of $1.741B rose 13.6% YoY after +16.7% in Q1 2026, +13.3% in Q4 2025, +14.7% in Q3 2025, and +10.6% in Q2 2025. Operating margin was 29.8% in Q2 2026 versus 28.1% a year earlier; Q4 2025 was a clear blip at 23.6% with net income of only $91M. GAAP EPS is noisy (Q3 2024’s $5.13 was an obvious one-off, and Q4 2025’s $0.16 was depressed), while adjusted Q2 2026 EPS of $0.78 beat the $0.74 consensus. Free cash flow rebounded to $585M in Q2 2026 after a seasonally negative Q1 2026 of -$21M.

The TTM P/E of 50.75 looks expensive but is distorted by depressed trailing GAAP EPS. Using the next-FY EPS estimate of $3.001, the forward P/E is about 29.4x, below the 5-year average P/E of 34.81x. P/S is 7.82x versus a 5-year average of 9.92x, and the negative PEG ratio is not meaningful. The stock is fairly valued to modestly attractive versus its own history, not cheap on absolute multiples.

The market is looking through messy trailing GAAP earnings and pricing a normalization toward $3.00 of forward EPS. If Edwards delivers high-end 28%-29% operating margins and mid-teens revenue growth, ~29x forward earnings is reasonable for a high-quality medtech franchise. If the FDA recall headline escalates or growth decelerates below low-double digits, the premium multiple becomes vulnerable.

As of 2026-10-20, RSI was 54.2—neutral, neither overbought nor oversold. The stock was 2.0% above its 20-day SMA, 0.2% below its 50-day SMA, and 3.5% above its 200-day SMA, consistent with a range-bound/mildly constructive trend inside the $74.66-$96.29 52-week range. Entry timing is neutral; there is no technical urgency to chase, and a pullback or the upcoming TCT/earnings catalysts are more relevant.

• Aging global population and rising prevalence of structural heart disease support durable TAVR/TMTT demand.
• Hospital capital budgets and procedure volumes remain sensitive to reimbursement policy and interest-rate-driven hospital financing costs.
• FDA safety scrutiny is elevated after the mid-October 2026 high-risk recall headline for a heart-valve delivery system.
• Global minimum tax rules, including Pillar Two safe-harbor dynamics, could modestly affect the tax rate in late 2026.
• Medtech sector rotation and competitive launches in transcatheter valves can compress valuation multiples even for quality franchises.

• TCT 2026 investor event and TAVR/TMTT pipeline Q&A in San Diego on 2026-11-02.
• Q3 2026 earnings on 2026-11-04, including updated full-year margin guidance.
• Resolution or escalation of the FDA high-risk recall involving the heart-valve delivery system.
• Commercial rollout of the newly approved AUTUS surgical pulmonary valve for pediatric patients.
• New clinical data on TAVR expansion indications and TMTT (mitral/tricuspid) therapies.

• The FDA recall could widen, damage device reliability perception, or trigger additional regulatory action.
• Competitive pressure in TAVR from Medtronic, Abbott, and other transcatheter valve programs could slow share gains.
• Pipeline setbacks or trial delays in TMTT would undercut the long-term growth premium.
• Reimbursement changes or hospital cost pressure could pressure pricing and procedure growth.
• A premium valuation leaves limited room for error if revenue growth decelerates or margins miss high-end guidance.
• Foreign exchange and evolving global tax rules could add earnings volatility.

Edwards is a high-quality structural heart leader with double-digit revenue growth, 78% gross margins, ~29% operating margins, net cash, and a forward P/E below its own five-year average. The risk/reward leans positive for long-term holders, but the premium multiple and the recent FDA recall headline cap near-term upside; this is a good business, not a screaming bargain.

Applied 31x to the next-FY EPS estimate of $3.001, a discount to the 5-year average trailing P/E of 34.81x but a premium to broader medtech, justified by 13%-16% revenue growth, 78% gross margin, ~29% operating margin, and a net-cash balance sheet.